Description:
The primary objective of this study is to determine the safety and feasibility of combining
cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy.
The secondary objectives of this trial are to determine pathologic complete response rates;
disease-free survival; to assess immune biomarkers of immunity (antigen-specific CD8+ T cell
immunity and TH2 T cells) in breast cancer biopsy specimens and blood samples in patients
receiving DC vaccinations; and to assess the feasibility of immunizing LA TNBC and ER+/HER2-
BC patients with patient-specific tumor antigens.
Title
- Brief Title: Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
- Official Title: Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
013-154
- NCT ID:
NCT02018458
Conditions
Interventions
Drug | Synonyms | Arms |
---|
LA TNBC: DC vaccine+Preop chemo | DC Vaccine - Dendritic Cell Vaccine, Preop chemo: Doxorubicin, Preop chemo: cyclophosphamide, Preop chemo: Paclitaxel, Preop chemo: Carboplatin | LA TNBC: DC vaccine+Preop chemo |
ER+/HER2-BC:DC vaccine+Preop chemo | DC Vaccination - Dendritic cell vaccination, Preop chemo - doxorubicin, Preop chemo - cyclophosphamide, Preop chemo - paclitaxel, Preop chemo: Carboplatin | ER+/HER2-BC:DC vaccine+Preop chemo |
Purpose
The primary objective of this study is to determine the safety and feasibility of combining
cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy.
The secondary objectives of this trial are to determine pathologic complete response rates;
disease-free survival; to assess immune biomarkers of immunity (antigen-specific CD8+ T cell
immunity and TH2 T cells) in breast cancer biopsy specimens and blood samples in patients
receiving DC vaccinations; and to assess the feasibility of immunizing LA TNBC and ER+/HER2-
BC patients with patient-specific tumor antigens.
Detailed Description
Recent studies have shown that human breast cancers can be immunogenic, and that enhancing
the immune effector function already present may augment the cytotoxic effects of standard
therapies.
vaccination remains the most attractive strategy because of its expected inducement of both
therapeutic T cell immunity (effector T cells) and protective T cell immunity (tumor-specific
memory T cells that can control tumor relapse). Several clinical studies have now
demonstrated that immunity against tumor antigens can be enhanced in cancer patients by
vaccination with ex vivo-generated tumor antigen-loaded dendritic cells (DCs). This strategy
capitalizes on the unique capacity of DCs to prime lymphocytes and to regulate and maintain
immune responses.
Our goals are to boost T cell immunity targeted against breast cancer utilizing a tumor
antigen-loaded DC vaccine, to enhance chemotherapy effectiveness and decrease tumor
metastagenicity, and to decrease the recurrence rates of LA TNBC and ER+/HER2- BC. Patients
will be treated with a combination of antigen-loaded DC vaccinations along with standard
preoperative chemotherapy, to improve immunogenicity and to increase the pCR rate achieved
with standard therapy. The trial will consist of 2 patient cohorts: TNBC and ER+/HER2- BC.
Trial Arms
Name | Type | Description | Interventions |
---|
LA TNBC: DC vaccine+Preop chemo | Experimental | LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost. | - LA TNBC: DC vaccine+Preop chemo
|
ER+/HER2-BC:DC vaccine+Preop chemo | Experimental | ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost. | - ER+/HER2-BC:DC vaccine+Preop chemo
|
Eligibility Criteria
- Inclusion Criteria:
A patient will be considered for enrollment in this study if all of the following criteria
are met:
1. Female patients ≥18 years of age.
2. Have either:
1. locally advanced TNBC defined as invasive ductal cancer; ER- tumors with <10% of
tumor nuclei immunoreactive; PR- tumors with <10% of tumor nuclei immunoreactive;
T3 or T4 disease, regardless of nodal status (T2 disease is eligible if there are
positive lymph nodes present by physical exam or imaging evaluation or
histological evaluation, OR
2. High-risk ER+ breast cancer defined as grade 3 invasive ductal or mixed
ductal/lobular cancers, or grade 2 with Ki67 ≥20%; node positive as evidenced by
physical exam or imaging evaluation or histological evaluation.
3. HER2- negative breast cancer. If HER2-, it is defined as follows:
1. FISH-negative (FISH ratio <2.0), or
2. IHC 0-1+, or
3. IHC 2+ AND FISH-negative (FISH ratio<2.0)
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
5. Adequate hematologic function, defined by:
1. Absolute neutrophil count (ANC) >1500/mm3
2. Platelet count ≥100,000/mm3
3. Hemoglobin >9 g/dL (in the absence of red blood cell transfusion)
6. Adequate liver function, defined by:
1. AST and ALT ≤2.5 x the upper limit of normal (ULN)
2. Total bilirubin ≤1.5 x ULN
7. Adequate renal function, defined by:
a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥60 ml/min
8. Patients with previous history of invasive cancers (including breast cancer) are
eligible if definitive treatment was completed more than 5 years prior to initiating
current study treatment, and there is no evidence of recurrent disease.
9. Eligible for treatment with paclitaxel, doxorubicin, cyclophosphamide and
carboplatine.
10. Patient must be accessible for treatment and follow-up.
11. Patients must be willing to undergo research biopsies to obtain breast cancer tissue
for whole exome sequencing and evaluation of tumor immune microenvironment.
12. All patients must be able to understand the investigational nature of the study and
give written informed consent prior to study entry.
- Exclusion Criteria:
A patient will be ineligible for inclusion in this study any of the following criteria are
met:
1. Evidence of metastatic disease on bone scan and CT scan of chest/abdomen (or PET CT
scan). Patients with intrathoracic metastatic adenopathy are eligible.
2. Active infection or unexplained fever >38.5°C during screening.
3. Active infections including viral hepatitis and HIV.
4. Active asthma or other condition requiring steroid therapy.
5. Autoimmune disease including lupus erythematosus or rheumatoid arthritis. Topical or
inhaled corticosteroids are allowed.
6. Patients who are currently receiving or who have received previous systemic therapy
for breast cancer (eg, chemotherapy, antibody therapy, targeted agents).The use of an
LHRH agonist during chemotherapy in premenopausal women who wish to preserve ovarian
function is allowed, but is not required.
7. Women who are pregnant or lactating. All patients with reproductive potential must
agree to use effective contraception from time of study entry until at least 3 months
after the last administration of study drug.
8. Have a NYHA Class III or IV CHF or LVEF <55%. Patients with significant cardiac
disease history within 1 year or ventricular arrhythmias requiring medication are also
excluded.
9. Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation such as:
1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of
the normal predicted value and/or O2 saturation that is 88% or less at rest on
room air
2. uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
3. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class
C).
10. History of any other disease, physical examination finding, or clinical laboratory
finding giving reasonable suspicion of a disease or condition that contraindicates use
of an investigational drug, or that might affect interpretation of the results of this
study, or render the patient at high risk for treatment complications.
11. Any other investigational or anti-cancer treatments while participating in this study.
12. Any other cancer
Maximum Eligible Age: | 80 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | Female |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Safety of DC Vaccine Combined With Chemotherapy |
Time Frame: | 4 years |
Safety Issue: | |
Description: | Toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 . This will include all patients (eligible and ineligible) who receive at least 1 inoculation of DC vaccine therapy. This safety population will also be used for the summaries and analysis of all safety parameters (drug exposure, tables of adverse events information, including serious adverse events, etc.). |
Secondary Outcome Measures
Measure: | Pathologic Complete Response Rate |
Time Frame: | 1 year |
Safety Issue: | |
Description: | Results are only reported for Arm 1, "LA TNBC: DC vaccine+preop chemo patients". Arm 2 did not enroll any patients.
The pathologic specimen will be graded per the tumor regression grading schema provided by the University of Texas MD Anderson Cancer Center "Residual Cancer Burden Calculator" at http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3. The following parameters are required from pathologic examination in order to calculate RCB: largest 2 dimensions of residual tumor bed in the breast; entire largest cross-sectional area of residual tumor bed; percentage of the tumor bed area that contains carcinoma; percentage of carcinoma in tumor bed that is in situ; number of positive (metastatic) lymph nodes; largest diameter of largest nodal metastasis. A pathologic complete response is defined as NO pathologic evidence of invasive disease in the breast or axillary lymph nodes. RCB-I (minimal cancer burden); RCB-II (moderate burden); and RCB-III (extensive burden). |
Measure: | Disease-free Survival |
Time Frame: | 36 months |
Safety Issue: | |
Description: | Results are only reported for Arm 1, "LA TNBC: DC vaccine+preop chemo patients". Arm 2, "ER+/HER2- BC: DC vaccine+preop chemo patients" did not enroll any patients with these hormone receptor criteria.
Analysis of disease-free survival ("DFS", reported in months) was calculated from the first day of treatment up to 36 months. |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Baylor Research Institute |
Trial Keywords
- Dendritic cell vaccine
- Breast Cancer
- Doxorubicin
- Paclitaxel
- Cyclophosphamide
- Carboplatin
Last Updated
May 13, 2021